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Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions.
It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of
apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due
to too much apoptosis, such as in the case of degenerative diseases while in others, too little apoptosis is the
culprit. Cancer is one of the scenarios where too little apoptosis occurs, resulting in malignant cells that will not
die. The mechanism of apoptosis is complex and involves many pathways. Defects can occur at any point along
these pathways, leading to malignant transformation of the affected cells, tumour metastasis and resistance to
anticancer drugs. Despite being the cause of problem, apoptosis plays an important role in the treatment of
cancer as it is a popular target of many treatment strategies. The abundance of literature suggests that targeting
apoptosis in cancer is feasible. However, many troubling questions arise with the use of new drugs or treatment
strategies that are designed to enhance apoptosis and critical tests must be passed before they can be used safely
in human subjects.
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1. Introduction
Cell death, particularly apoptosis, is probably one of the
most widely-studied subjects among cell biologists.
Understanding apoptosis in disease conditions is very
important as it not only gives insights into the patho-
genesis of a disease but may also leaves clues on how
the disease can be treated. In cancer, there is a loss of
balance between cell division and cell death and cells
that should have died did not receive the signals to do
so. The problem can arise in any one step along the way
of apoptosis. One example is the downregulation of p53,
a tumour suppressor gene, which results in reduced
apoptosis and enhanced tumour growth and develop-
ment [1] and inactivation of p53, regardless of the
mechanism, has been linked to many human cancers
[2-4]. However, being a double-edged sword, apoptosis
can be cause of the problem as well as the solution, as
many have now ventured into the quest of new drugs
targeting various aspects of apoptosis [5,6]. Hence,
apoptosis plays an important role in both carcinogenesis
and cancer treatment. This article gives a comprehensive
review of apoptosis, its mechanisms, how defects along
the apoptotic pathway contribute to carcinogenesis and
how apoptosis can be used as a vehicle of targeted treat-
ment in cancer.
2. Apoptosis
The term “apoptosis” is derived from the Greek words
“aπο“ and “πτωsιζ“ meaning “dropping off” and refers
to the falling of leaves from trees in autumn. It is used,
in contrast to necrosis, to describe the situation in
which a cell actively pursues a course toward death
upon receiving certain stimuli [7]. Ever since apoptosis
was described by Kerr et al in the 1970’s, it remains one
of the most investigated processes in biologic research
[8]. Being a highly selective process, apoptosis is impor-
tant in both physiological and pathological conditions
[9,10]. These conditions are summarised in Table 1.
2.1 Morphological changes in apoptosis
Morphological alterations of apoptotic cell death that
concern both the nucleus and the cytoplasm are
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remarkably similar across cell types and species [11,12].
Usually several hours are required from the initiation of
cell death to the final cellular fragmentation. However,
the time taken depends on the cell type, the stimulus
and the apoptotic pathway [13].
Morphological hallmarks of apoptosis in the nucleus
are chromatin condensation and nuclear fragmentation,
which are accompanied by rounding up of the cell,
reduction in cellular volume (pyknosis) and retraction of
pseudopodes [14]. Chromatin condensation starts at the
periphery of the nuclear membrane, forming a crescent
or ring-like structure. The chromatin further condenses
until it breaks up inside a cell with an intact membrane,
a feature described as karyorrhexis [15]. The plasma
membrane is intact throughout the total process. At the
later stage of apoptosis some of the morphological fea-
tures include membrane blebbing, ultrastrutural modifi-
cation of cytoplasmic organelles and a loss of membrane
integrity [14]. Usually phagocytic cells engulf apoptotic
cells before apoptotic bodies occur. This is the reason
why apoptosis was discovered very late in the history of
cell biology in 1972 and apoptotic bodies are seen in
vitro under special conditions. If the remnants of apop-
totic cells are not phagocytosed such as in the case of
an artificial cell culture environment, they will undergo
degradation that resembles necrosis and the condition is
termed secondary necrosis [13].
2.2 Biochemical changes in apoptosis
Broadly, three main types of biochemical changes can
be observed in apoptosis: 1) activation of caspases, 2)
DNA and protein breakdown and 3) membrane
changes and recognition by phagocytic cells [16]. Early
in apoptosis, there is expression of phosphatidylserine
(PS) in the outer layers of the cell membrane, which
has been “flipped out” from the inner layers. This
allows early recognition of dead cells by macrophages,
resulting in phagocytosis without the release of pro-
inflammatory cellular components [17]. This is fol-
lowed by a characteristic breakdown of DNA into large
50 to 300 kilobase pieces [18]. Later, there is internu-
cleosomal cleavage of DNA into oligonucleosomes in
multiples of 180 to 200 base pairs by endonucleases.
Although this feature is characteristic of apoptosis, it is
not specific as the typical DNA ladder in agarose gel
electrophoresis can be seen in necrotic cells as well
[19]. Another specific feature of apoptosis is the activa-
tion of a group of enzymes belonging to the cysteine
protease family named caspases. The “c” of “caspase”
refers to a cysteine protease, while the “aspase” refers
to the enzyme’s unique property to cleave after aspar-
tic acid residues [16]. Activated caspases cleave many
vital cellular proteins and break up the nuclear scaffold
and cytoskeleton. They also activate DNAase, which
further degrade nuclear DNA [20]. Although the bio-
chemical changes explain in part some of the morpho-
logical changes in apoptosis, it is important to note
that biochemical analyses of DNA fragmentation or
caspase activation should not be used to define apop-
tosis, as apoptosis can occur without oligonucleosomal
DNA fragmentation and can be caspase-independent
[21]. While many biochemical assays and experiments
have been used in the detection of apoptosis, the
Nomenclature Committee on Cell Death (NCCD) has
proposed that the classification of cell death modalities
should rely purely on morphological criteria because
there is no clear-cut equivalence between ultrastruc-
tural changes and biochemical cell death characteristics
[21].
2.3 Mechanisms of apoptosis
Understanding the mechanisms of apoptosis is crucial
and helps in the understanding of the pathogenesis of
conditions as a result of disordered apoptosis. This in
turn, may help in the development of drugs that target
certain apoptotic genes or pathways. Caspases are cen-
tral to the mechanism of apoptosis as they are both
the initiators and executioners. There are three path-
ways by which caspases can be activated. The two
commonly described initiation pathways are the intrin-
sic (or mitochondrial) and extrinsic (or death receptor)
pathways of apoptosis (Figure 1). Both pathways even-
tually lead to a common pathway or the execution
phase of apoptosis. A third less well-known initiation
pathway is the intrinsic endoplasmic reticulum path-
way [22].
Table 1 Conditions involving apoptosis
Physiological conditions
Programmed cell destruction in embryonic development for the
purpose of sculpting of tissue
Physiologic involution such as shedding of the endometrium, regression
of the lactating breast
Normal destruction of cells accompanied by replacement proliferation
such as in the gut epithelium
Involution of the thymus in early age
Pathological conditions
Anticancer drug induced cell death in tumours
Cytotoxic T cell induced cell death such as in immune rejection and
graft versus host disease
Progressive cell death and depletion of CD4+ cells in AIDs
Some forms of virus-induced cell death, such as hepatitis B or C
Pathologic atrophy of organs and tissues as a result of stimuli removal
e.g. prostatic atrophy after orchidectomy
Cell death due to injurious agents like radiation, hypoxia and mild
thermal injury
Cell death in degenerative diseases such as Alzheimer’s disease and
Parkinson’s disease
Cell death that occurs in heart diseases such as myocardial infarction
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2.3.1 The extrinsic death receptor pathway
The extrinsic death receptor pathway, as its name
implies, begins when death ligands bind to a death
receptor. Although several death receptors have been
described, the best known death receptors is the type 1
TNF receptor (TNFR1) and a related protein called Fas
(CD95) and their ligands are called TNF and Fas ligand
(FasL) respectively [17]. These death receptors have an
intracellular death domain that recruits adapter proteins
such as TNF receptor-associated death domain
(TRADD) and Fas-associated death domain (FADD), as
well as cysteine proteases like caspase 8 [23]. Binding of
the death ligand to the death receptor results in the for-
mation of a binding site for an adaptor protein and the
whole ligand-receptor-adaptor protein complex is
known as the death-inducing signalling complex (DISC)
[22]. DISC then initiates the assembly and activation of
pro-caspase 8. The activated form of the enzyme, cas-
pase 8 is an initiator caspase, which initiates apoptosis
by cleaving other downstream or executioner caspases
[24].
2.3.2 The intrinsic mitochondrial pathway
As its name implies, the intrinsic pathway is initiated
within the cell. Internal stimuli such as irreparable
genetic damage, hypoxia, extremely high concentrations
of cytosolic Ca2+ and severe oxidative stress are some
triggers of the initiation of the intrinsic mitochondrial
pathway [24]. Regardless of the stimuli, this pathway is
the result of increased mitochondrial permeability and
the release of pro-apoptotic molecules such as cyto-
chrome-c into the cytoplasm [25]. This pathway is clo-
sely regulated by a group of proteins belonging to the
Bcl-2 family, named after the BCL2 gene originally
observed at the chromosomal breakpoint of the translo-
cation of chromosome 18 to 14 in follicular non-Hodg-
kin lymphoma [26]. There are two main groups of the
Bcl-2 proteins, namely the pro-apoptotic proteins (e.g.
Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim and Hrk) and the
anti-apoptotic proteins (e.g. Bcl-2, Bcl-XL, Bcl-W, Bfl-1
and Mcl-1) [27]. While the anti-apoptotic proteins regu-
late apoptosis by blocking the mitochondrial release of
cytochrome-c, the pro-apoptotic proteins act by promot-
ing such release. It is not the absolute quantity but
rather the balance between the pro- and anti-apoptotic
proteins that determines whether apoptosis would be
initiated [27]. Other apoptotic factors that are released
from the mitochondrial intermembrane space into the
cytoplasm include apoptosis inducing factor (AIF), sec-
ond mitochondria-derived activator of caspase (Smac),
direct IAP Binding protein with Low pI (DIABLO) and
Omi/high temperature requirement protein A (HtrA2)
[28]. Cytoplasmic release of cytochrome c activates cas-
pase 3 via the formation of a complex known as apopto-
some which is made up of cytochrome c, Apaf-1 and
caspase 9 [28]. On the other hand, Smac/DIABLO or
Omi/HtrA2 promotes caspase activation by binding to
inhibitor of apoptosis proteins (IAPs) which subse-
quently leads to disruption in the interaction of IAPs
with caspase-3 or -9 [28,29].
2.3.3 The common pathway
The execution phase of apoptosis involves the activation
of a series of caspases. The upstream caspase for the
intrinsic pathway is caspase 9 while that of the extrinsic
pathway is caspase 8. The intrinsic and extrinsic path-
ways converge to caspase 3. Caspase 3 then cleaves the
inhibitor of the caspase-activated deoxyribonuclease,
which is responsible for nuclear apoptosis [30]. In addi-
tion, downstream caspases induce cleavage of protein
kinases, cytoskeletal proteins, DNA repair proteins and
inhibitory subunits of endonucleases family. They also
have an effect on the cytoskeleton, cell cycle and signal-
ling pathways, which together contribute to the typical
morphological changes in apoptosis [30].
2.3.4 The intrinsic endoplasmic reticulum pathway
This intrinsic endoplasmic reticulum (ER) pathway is a
third pathway and is less well known. It is believed to
be caspase 12-dependent and mitochondria-independent
[31]. When the ER is injured by cellular stresses like
hypoxia, free radicals or glucose starvation, there is
Figure 1 The intrinsic and extrinsic pathways of apoptosis.
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unfolding of proteins and reduced protein synthesis in
the cell, and an adaptor protein known as TNF receptor
associated factor 2 (TRAF2) dissociates from procas-
pase-12, resulting in the activation of the latter [22].
3. Apoptosis and carcinogenesis
Cancer can be viewed as the result of a succession of
genetic changes during which a normal cell is trans-
formed into a malignant one while evasion of cell death
is one of the essential changes in a cell that cause this
malignant transformation [32]. As early as the 1970’s,
Kerr et al had linked apoptosis to the elimination of
potentially malignant cells, hyperplasia and tumour pro-
gression [8]. Hence, reduced apoptosis or its resistance
plays a vital role in carcinogenesis. There are many ways
a malignant cell can acquire reduction in apoptosis or
apoptosis resistance. Generally, the mechanisms by
which evasion of apoptosis occurs can be broadly divi-
dend into: 1) disrupted balance of pro-apoptotic and
anti-apoptotic proteins, 2) reduced caspase function and
3) impaired death receptor signalling. Figure 2
summarises the mechanisms that contribute to evasion
of apoptosis and carcinogenesis.
3.1 Disrupted balance of pro-apoptotic and anti-apoptotic
proteins
Many proteins have been reported to exert pro- or anti-
apoptotic activity in the cell. It is not the absolute quan-
tity but rather the ratio of these pro-and anti-apoptotic
proteins that plays an important role in the regulation
of cell death. Besides, over- or under-expression of cer-
tain genes (hence the resultant regulatory proteins) have
been found to contribute to carcinogenesis by reducing
apoptosis in cancer cells.
3.1.1 The Bcl-2 family of proteins
The Bcl-2 family of proteins is comprised of pro-apop-
totic and anti-apoptotic proteins that play a pivotal role
in the regulation of apoptosis, especially via the intrinsic
pathway as they reside upstream of irreversible cellular
damage and act mainly at the mitochondria level [33].
Bcl-2 was the first protein of this family to be identified
more than 20 years ago and it is encoded by the BCL2
Figure 2 Mechanisms contributing to evasion of apoptosis and carcinogenesis.
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gene, which derives its name from B-cell lymphoma 2,
the second member of a range of proteins found in
human B-cell lymphomas with the t (14; 18) chromoso-
mal translocation [26].
All the Bcl-2 members are located on the outer mito-
chondrial membrane. They are dimmers which are
responsible for membrane permeability either in the
form of an ion channel or through the creation of pores
[34]. Based of their function and the Bcl-2 homology
(BH) domains the Bcl-2 family members are further
divided into three groups [35]. The first group are the
anti-apoptotic proteins that contain all four BH domains
and they protect the cell from apoptotic stimuli. Some
examples are Bcl-2, Bcl-xL, Mcl-1, Bcl-w, A1/Bfl-1, and
Bcl-B/Bcl2L10. The second group is made up of the
BH-3 only proteins, so named because in comparison to
the other members, they are restricted to the BH3
domain. Examples in this group include Bid, Bim, Puma,
Noxa, Bad, Bmf, Hrk, and Bik. In times of cellular stres-
ses such as DNA damage, growth factor deprivation and
endoplasmic reticulum stress, the BH3-only proteins,
which are initiators of apoptosis, are activated. There-
fore, they are pro-apoptotic. Members of the third
group contain all four BH domains and they are also
pro-apoptotic. Some examples include Bax, Bak, and
Bok/Mtd [35].
When there is disruption in the balance of anti-apop-
totic and pro-apoptotic members of the Bcl-2 family,
the result is dysregulated apoptosis in the affected cells.
This can be due to an overexpression of one or more
anti-apoptotic proteins or an underexpression of one or
more pro-apoptotic proteins or a combination of both.
For example, Raffo et al showed that the overexpression
of Bcl-2 protected prostate cancer cells from apoptosis
[36] while Fulda et al reported Bcl-2 overexpression led
to inhibition of TRAIL-induced apoptosis in neuroblas-
toma, glioblastoma and breast carcinoma cells [37].
Overexpression of Bcl-xL has also been reported to con-
fer a multi-drug resistance phenotype in tumour cells
and prevent them from undergoing apoptosis [38]. In
colorectal cancers with microsatellite instability, on the
other hand, mutations in the bax gene are very com-
mon. Miquel et al demonstrated that impaired apoptosis
resulting from bax(G)8 frameshift mutations could con-
tribute to resistance of colorectal cancer cells to antican-
cer treatments [39]. In the case of chronic lymphocytic
leukaemia (CLL), the malignant cells have an anti-apop-
totic phenotype with high levels of anti-apoptotic Bcl-2
and low levels of pro-apoptotic proteins such as Bax in
vivo. Leukaemogenesis in CLL is due to reduced apopto-
sis rather than increased proliferation in vivo [40]. Pep-
per et al reported that B-lymphocytes in CLL showed
an increased Bcl-2/Bax ratio in patients with CLL and
that when these cells were cultured in vitro, drug-
induced apoptosis in B-CLL cells was inversely related
to Bcl-2/Bax ratios [41].
3.1.2 p53
The p53 protein, also called tumour protein 53 (or TP
53), is one of the best known tumour suppressor pro-
teins encoded by the tumour suppressor gene TP53
located at the short arm of chromosome 17 (17p13.1). It
is named after its molecular weights, i.e., 53 kDa [42]. It
was first identified in 1979 as a transformation-related
protein and a cellular protein accumulated in the nuclei
of cancer cells binding tightly to the simian virus 40
(SV40) large T antigen. Initially, it was found to be
weakly-oncogenic. It was later discovered that the onco-
genic property was due to a p53 mutation, or what was
later called a “gain of oncogenic function” [43]. Since its
discovery, many studies have looked into its function
and its role in cancer. It is not only involved in the
induction of apoptosis but it is also a key player in cell
cycle regulation, development, differentiation, gene
amplification, DNA recombination, chromosomal segre-
gation and cellular senescence [44] and is called the
“guardian of the genome” [45].
Defects in the p53 tumour suppressor gene have been
linked to more than 50% of human cancers [43].
Recently, Avery-Kieida et al reported that some target
genes of p53 involved in apoptosis and cell cycle regula-
tion are aberrantly expressed in melanoma cells, leading
to abnormal activity of p53 and contributing to the pro-
liferation of these cells [46]. In a mouse model with an
N-terminal deletion mutant of p53 (Δ122p53) that corre-
sponds to Δ133p53, Slatter et al demonstrated that these
mice had decreased survival, a different and more aggres-
sive tumor spectrum, a marked proliferative advantage
on cells, reduced apoptosis and a profound proinflamma-
tory phenotype [47]. In addition, it has been found that
when the p53 mutant was silenced, such down-regulation
of mutant p53 expression resulted in reduced cellular
colony growth in human cancer cells, which was found
to be due to the induction of apoptosis [48].
3.1.3 Inhibitor of apoptosis proteins (IAPs)
The inhibitor of apoptosis proteins are a group of struc-
turally and functionally similar proteins that regulate
apoptosis, cytokinesis and signal transduction. They are
characterised by the presence of a baculovirus IAP
repeat (BIR) protein domain [29]. To date eight IAPs
have been identified, namely, NAIP (BIRC1), c-IAP1
(BIRC2), c-IAP2 (BIRC3), X-linked IAP (XIAP, BIRC4),
Survivin (BIRC5), Apollon (BRUCE, BIRC6), Livin/ML-
IAP (BIRC7) and IAP-like protein 2 (BIRC8) [49]. IAPs
are endogenous inhibitors of caspases and they can inhi-
bit caspase activity by binding their conserved BIR
domains to the active sites of caspases, by promoting
degradation of active caspases or by keeping the cas-
pases away from their substrates [50].
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Dysregulated IAP expression has been reported in
many cancers. For example, Lopes et al demonstrated
abnormal expression of the IAP family in pancreatic
cancer cells and that this abnormal expression was
also responsible for resistance to chemotherapy.
Among the IAPs tested, the study concluded that drug
resistance correlated most significantly with the
expression of cIAP-2 in pancreatic cells [51]. On the
other hand, Livin was demonstrated to be highly
expressed in melanoma and lymphoma [52,53] while
Apollon, was found to be upregulated in gliomas and
was responsible for cisplatin and camptothecin resis-
tance [54]. Another IAP, Survivin, has been reported
to be overexpressed in various cancers. Small et al.
observed that transgenic mice that overexpressed Sur-
vivin in haematopoietic cells were at an increased risk
of haematological malignancies and that haematopoie-
tic cells engineered to overexpress Survivin were less
susceptible to apoptosis [55]. Survivin, together with
XIAP, was also found to be overexpressed in non-
small cell lung carcinomas (NSCLCs) and the study
concluded that the overexpression of Survivin in the
majority of NSCLCs together with the abundant or
upregulated expression of XIAP suggested that these
tumours were endowed with resistance against a vari-
ety of apoptosis-inducing conditions [56].
3.2 Reduced capsase activity
The caspases can be broadly classified into two groups:
1) those related to caspase 1 (e.g. caspase-1, -4, -5, -13,
and -14) and are mainly involved in cytokine processing
during inflammatory processes and 2) those that play a
central role in apoptosis (e.g. caspase-2, -3. -6, -7,-8, -9
and -10). The second group can be further classified
into 1) initiator caspases (e.g. caspase-2, -8, -9 and -10)
which are primarily responsible for the initiation of the
apoptotic pathway and 2) effector caspases (caspase-3,
-6 and -7) which are responsible in the actual cleavage
of cellular components during apoptosis [57]. As men-
tioned in Section 2.2, caspases remain one of the impor-
tant players in the initiation and execution of apoptosis.
It is therefore reasonable to believe that low levels of
caspases or impairment in caspase function may lead to
a decreased in apoptosis and carcinogenesis.
In one study, downregulation of caspase-9 was found
to be a frequent event in patients with stage II colorectal
cancer and correlates with poor clinical outcome [58].
In another study, Devarajan et al observed that cas-
pases-3 mRNA levels in commercially available total
RNA samples from breast, ovarian, and cervical tumuors
were either undetectable (breast and cervical) or sub-
stantially decreased (ovarian) and that the sensitivity of
caspase-3-deficient breast cancer (MCF-7) cells to
undergo apoptosis in response to anticancer drug or
other stimuli of apoptosis could be enhanced by restor-
ing caspase-3 expression, suggesting that the loss of cas-
pases-3 expression and function could contribute to
breast cancer cell survival [59]. In some instances, more
than one caspase can be downregulated, contributing to
tumour cell growth and development. In a cDNA array
differential expression study, Fong et al observed a co-
downregulation of both capase-8 and -10 and postulated
that it may contribute to the pathogenesis of choriocar-
cinoma [60].
3.3 Impaired death receptor signalling
Death receptors and ligands of the death receptors are
key players in the extrinsic pathway of apoptosis. Other
than TNFR1 (also known as DR 1) and Fas (also known
as DR2, CD95 or APO-1) mentioned in Section 2.3,
examples of death receptors include DR3 (or APO-3),
DR4 [or TNF-related apoptosis inducing ligand receptor
1 (TRAIL-1) or APO-2], DR5 (or TRAIL-2), DR 6, ecto-
dysplasin A receptor (EDAR) and nerve growth factor
receptor (NGFR) [61]. These receptors posses a death
domain and when triggered by a death signal, a number
of molecules are attracted to the death domain, resulting
in the activation of a signalling cascade. However, death
ligands can also bind to decoy death receptors that do
not posses a death domain and the latter fail to form
signalling complexes and initiate the signalling cascade
[61]
Several abnormalities in the death signalling pathways
that can lead to evasion of the extrinsic pathway of
apoptosis have been identified. Such abnormalities
include downregulation of the receptor or impairment
of receptor function regardless of the mechanism or
type of defects, as well as a reduced level in the death
signals, all of which contribute to impaired signalling
and hence a reduction of apoptosis. For instance, down-
regulation of receptor surface expression has been indi-
cated in some studies as a mechanism of acquired drug
resistance. A reduced expression of CD95 was found to
play a role in treatment-resistant leukaemia [62] or neu-
roblastoma [63] cells. Reduced membrane expression of
death receptors and abnormal expression of decoy
receptors have also been reported to play a role in the
evasion of the death signalling pathways in various can-
cers [64]. In a study carried out to examine if changes
in death ligand and death receptor expression during
different stages of cervical carcinogenesis were related
to an imbalance between proliferation and apoptosis,
Reesink-Peters et al concluded that the loss of Fas and
the dysregulation of FasL, DR4, DR5, and tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL) in
the cervical intraepithelial neoplasia (CIN)-cervical can-
cer sequence might be responsible for cervical carcino-
genesis [65].
Wong Journal of Experimental & Clinical Cancer Research 2011, 30:87
http://www.jeccr.com/content/30/1/87
Page 6 of 14
4. Targeting apoptosis in cancer treatment
Like a double-edged sword, every defect or abnormality
along the apoptotic pathways may also be an interesting
target of cancer treatment. Drugs or treatment strategies
that can restore the apoptotic signalling pathways
towards normality have the potential to eliminate cancer
cells, which depend on these defects to stay alive. Many
recent and important discoveries have opened new
doors into potential new classes of anticancer drugs.
This Section emphasises on new treatment options tar-
geting some of the apoptotic defects mentioned in Sec-
tion 3. A summary of these drugs and treatment
strategies is given in Table 2.
4.1 Targeting the Bcl-2 family of proteins
Some potential treatment strategies used in targeting the
Bcl-2 family of proteins include the use of therapeutic
agents to inhibit the Bcl-2 family of anti-apoptotic pro-
teins or the silencing of the upregulated anti-apoptotic
proteins or genes involved.
4.1.1Agents that target the Bcl-2 family of proteins
One good example of these agents is the drug oblimer-
sen sodium, which is a Bcl-2 antisence oblimer, the first
agent targeting Bcl-2 to enter clinical trial. The drug has
been reported to show chemosensitising effects in com-
bined treatment with conventional anticancer drugs in
chronic myeloid leukaemia patients and an improve-
ment in survival in these patients [66,67]. Other exam-
ples included in this category are the small molecule
inhibitors of the Bcl-2 family of proteins. These can be
further divided into: 1) those molecules that affect gene
or protein expression and 2) those acting on the pro-
teins themselves. Examples for the first group include
sodium butyrate, depsipetide, fenretinide and flavipiro-
dol while the second group includes gossypol, ABT-737,
ABT-263, GX15-070 and HA14-1 (reviewed by Kang
and Reynold, 2009 [68]).
Some of these small molecules belong to yet another
class of drugs called BH3 mimetics, so named because
they mimic the binding of the BH3-only proteins to the
hydrophobic groove of anti-apoptotic proteins of the
Bcl-2 family. One classical example of a BH3 mimetic is
ABT-737, which inhibits anti-apoptotic proteins such as
Bcl-2, Bcl-xL, and Bcl-W. It was shown to exhibit cyto-
toxicity in lymphoma, small cell lung carcinoma cell line
and primary patient-derived cells and caused regression
of established tumours in animal models with a high
percentage of cure [69]. Other BH3 mimetics such as
ATF4, ATF3 and NOXA have been reported to bind to
and inhibit Mcl-1 [70].
4.1.2 Silencing the anti-apoptotic proteins/genes
Rather than using drugs or therapeutic agents to inhibit
the anti-apoptotic members of the Bcl-2 family, some
studies have demonstrated that by silencing genes
coding for the Bcl-2 family of anti-apoptotic proteins, an
increase in apoptosis could be achieved. For example,
the use of Bcl-2 specific siRNA had been shown to spe-
cifically inhibit the expression of target gene in vitro and
in vivo with anti-proliferative and pro-apoptotic effects
observed in pancreatic carcinoma cells [71]. On the
other hand, Wu et al demonstrated that by silencing
Bmi-1 in MCF breast cancer cells, the expression of
pAkt and Bcl-2 was downregulated, rendering these
cells more sensitive to doxorubicin as evidenced by an
increase in apoptotic cells in vitro and in vivo [72].
4.2 Targeting p53
Many p53-based strategies have been investigated for
cancer treatment. Generally, these can be classified into
three broad categories: 1) gene therapy, 2) drug therapy
and 3) immunotherapy.
4.2.1 p53-based gene therapy
The first report of p53 gene therapy in 1996 investigated
the use of a wild-type p53 gene containing retroviral
vector injected into tumour cells of non-small cell lung
carcinoma derived from patients and showed that the
use of p53-based gene therapy may be feasible [73]. As
the use of the p53 gene alone was not enough to elimi-
nate all tumour cells, later studies have investigated the
use of p53 gene therapy concurrently with other antic-
ancer strategies. For example, the introduction of wild-
type p53 gene has been shown to sensitise tumour cells
of head and neck, colorectal and prostate cancers and
glioma to ionising radiation [74]. Although a few studies
managed to go as far as phase III clinical trials, no final
approval from the FDA has been granted so far [75].
Another interesting p53 gene-based strategy was the use
of engineered viruses to eliminate p53-deficient cells.
One such example is the use of a genetically engineered
oncolytic adenovirus, ONYX-015, in which the E1B-55
kDa gene has been deleted, giving the virus the ability
to selectively replicate in and lyse tumour cells deficient
in p53 [76].
4.2.2 p53-based drug therapy
Several drugs have been investigated to target p53 via
different mechanisms. One class of drugs are small
molecules that can restore mutated p53 back to their
wild-type functions. For example, Phikan083, a small
molecule and carbazole derivative, has been shown to
bind to and restore mutant p53 [77]. Another small
molecule, CP-31398, has been found to intercalate with
DNA and alter and destabilise the DNA-p53 core
domain complex, resulting in the restoration of unstable
p53 mutants [78]. Other drugs that have been used to
target p53 include the nutlins, MI-219 and the tenovins.
Nutlins are analogues of cis-imidazoline, which inhibit
the MSM2-p53 interaction, stabilise p53 and selectively
induce senescence in cancer cells [79] while MI-219 was
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Table 2 Summary of treatment strategies targeting apoptosis
Treatment strategy Remarks Author/reference
Targeting the Bcl-2 family of
proteins
Agents that target the Bcl-2
family proteins
Oblimersen sodium
Reported to show chemosensitising effects in combined treatment with
conventional anticancer drugs in chronic myeloid leukaemia patients and an
improvement in survival in these patients
Rai et al., 2008 [66], Abou-
Nassar and Brown, 2010 [67]
Small molecule inhibitors of the Bcl-2 family of proteins
Molecules reported to affect gene or protein expression include sodium butyrate,
depsipetide, fenretinide and flavipirodo. Molecules reported to act on the proteins
themselves include gossypol, ABT-737, ABT-263, GX15-070 and HA14-1
Kang and Reynold, 2009 [68]
BH3 mimetics
ABT-737 reported to inhibit anti-apoptotic proteins such as Bcl-2, Bcl-xL, and Bcl-W
and to exhibit cytotoxicity in lymphoma, small cell lung carcinoma cell line and
primary patient-derived cells
Oltersdorf et al., 2005 [69]
ATF4, ATF3 and NOXA reported to bind to and inhibit Mcl-1 Albershardt et al., 2011 [70]
Silencing the Bcl family anti-
apoptotic proteins/genes
Bcl-2 specific siRNA reported to specifically inhibit the expression of target gene in
vitro and in vivo with anti-proliferative and pro-apoptotic effects observed in
pancreatic carcinoma cells
Ocker et al., 2005 [71]
Silencing Bmi-1 in MCF breast cancer cells reported to downregulate the
expression of pAkt and Bcl-2 and to increase sensitivity of these cells to
doxorubicin with an increase in apoptotic cells in vitro and in vivo
Wu et al., 2011 [72]
Targeting p53
p53-based gene therapy First report on the use of a wild-type p53 gene containing retroviral vector injected
into tumour cells of non-small cell lung carcinoma derived from patients. The use
of p53-based gene therapy was reported to be feasible.
Roth et al., 1996 [73]
Introduction of wild type p53 gene reported to sensitise tumour cells of head and
neck, colorectal and prostate cancers and glioma to ionising radiation
Chène, 2001 [74]
Genetically engineered oncolytic adenovirus, ONYX-015 reported to selectively
replicate in and lyse tumour cells deficient in p53
Nemunaitis et al., 2009 [76]
p53-based drug therapy Small molecules
Phikan083 reported to bind to and restore mutant p53 Boeckler et al., 2008 [77]
CP-31398 reported to intercalate with DNA and alter and destabilise the DNA-p53
core domain complex, resulting in the restoration of unstable p53 mutants
Rippin et al., 2002 [78]
Other agents
Nutlins reported to inhibit the MSM2-p53 interaction, stabilise p53 and selectively
induce senescence in cancer cells
Shangery and Wang, 2008
[79]
MI-219 reported to disrupt the MDM2-p53 interaction, resulting in inhibition of cell
proliferation, selective apoptosis in tumour cells and complete tumour growth
inhibition
Shangery et al., 2008 [80]
Tenovins reported to decrease tumour growth in vivo Lain et al., 2008 [81]
p53-based immunotherapy Patients with advanced stage cancer given vaccine containing a recombinant
replication-defective adenoviral vector with human wild-type p53 reported to have
stable disease
Kuball et al., 2002 [82]
Clinical and p53-specific T cell responses observed in patients given p53 peptide
pulsed dendritic cells in a phase I clinical trial
Svane et al., 2004 [83]
Targeting IAPS
Targeting XIAP Antisense approach
Reported to result in an improved in vivo tumour control by radiotherapy Cao et al., 2004 [86]
Concurrent use of antisense oligonucleotides and chemotherapy reported to
exhibit enhanced chemotherapeutic activity in lung cancer cells in vitro and in vivo
Hu et al., 2003 [87]
siRNA approach
siRNA targeting of XIAP reported to increase radiation sensitivity of human cancer
cells independent of TP53 status
Ohnishi et al., 2006 [88]
Targeting XIAP or Survivin by siRNAs sensitised hepatoma cells to death receptor-
and chemotherapeutic agent-induced cell death
Yamaguchi et al., 2005 [89]
Targeting Survivin Antisense approach
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reported to disrupt the MDM2-p53 interaction, resulting
in inhibition of cell proliferation, selective apoptosis in
tumour cells and complete tumour growth inhibition
[80]. The tenovins, on the other hand, are small mole-
cule p53 activators, which have been shown to decrease
tumour growth in vivo [81].
4.2.3 p53-based immunotherapy
Several clinical trials have been carried out using p53
vaccines. In a clinical trial by Kuball et al, six patients
with advanced-stage cancer were given vaccine con-
taining a recombinant replication-defective adenoviral
vector with human wild-type p53. When followed up
at 3 months post immunisation, four out of the six
patients had stable disease. However, only one patient
had stable disease from 7 months onwards [82]. Other
than viral-based vaccines, dendritic-cell based vaccines
have also been attempted in clinical trials. Svane et al
tested the use of p53 peptide pulsed dendritic cells in
a phase I clinical trial and reported a clinical response
in two out of six patients and p53-specific T cell
responses in three out of six patients [83]. Other vac-
cines that have been used including short peptide-
based and long peptide-based vaccines (reviewed by
Vermeij R et al., 2011 [84]).
4.3 Targeting the IAPs
4.3.1 Targeting XIAP
When designing novel drugs for cancers, the IAPs are
attractive molecular targets. So far, XIAP has been
reported to be the most potent inhibitor of apoptosis
among all the IAPs. It effectively inhibits the intrinsic as
well as extrinsic pathways of apoptosis and it does so by
binding and inhibiting upstream caspase-9 and the
downstream caspases-3 and -7 [85]. Some novel therapy
targeting XIAP include antisense strategies and short
interfering RNA (siRNA) molecules. Using the antisense
approach, inhibition of XIAP has been reported to result
in an improved in vivo tumour control by radiotherapy
[86]. When used together with anticancer drugs XIAP
antisense oligonucleotides have been demonstrated to
exhibit enhanced chemotherapeutic activity in lung can-
cer cells in vitro and in vivo [87]. On the other hand,
Ohnishi et al reported that siRNA targeting of XIAP
increased radiation sensitivity of human cancer cells
Table 2 Summary of treatment strategies targeting apoptosis (Continued)
Transfection of anti-sense Survivin into YUSAC-2 and LOX malignant melanoma
cells reported to result in spontaneous apoptosis
Grossman et al., 1999 [90]
Reported to induce apoptosis and sensitise head and neck squamous cell
carcinoma cells to chemotherapy
Sharma et al., 2005 [91]
Reported to inhibit growth and proliferation of medullary thyroid carcinoma cells Du et al., 2006 [92]
siRNA approach
Reported o downregulate Survivin and diminish radioresistance in pancreatic
cancer cells
Kami et al., 2005 [93]
Reported to inhibit proliferation and induce apoptosis in SPCA1 and SH77 human
lung adenocarcinoma cells
Liu et al., 2011 [94]
Reported to suppress Survivin expression, inhibit cell proliferation and enhance
apoptosis in SKOV3/DDP ovarian cancer cells
Zhang et al., 2009 [95]
Reported to enhance the radiosensitivity of human non-small cell lung cancer cells Yang et al., 2010 [96]
Other IAP antagonists Small molecules antagonists
Cyclin-dependent kinase inhibitors and Hsp90 inhibitors and gene therapy
attempted in targeting Survivin in cancer therapy
Pennati et al., 2007 [97]
Cyclopeptidic Smac mimetics 2 and 3 report to bind to XIAP and cIAP-1/2 and
restore the activities of caspases- 9 and 3/-7 inhibited by XIAP
Sun et al., 2010 [98]
SM-164 reported to enhance TRAIL activity by concurrently targeting XIAP and
cIAP1
Lu et al., 2011 [99]
Targeting caspases
Caspase-based drug therapy Apoptin reported to selectively induce apoptosis in malignant but not normal cells Rohn et al, 2004 [100]
Small molecules caspase activators reported to lower the activation threshold of
caspase or activate caspase, contributing to an increased drug sensitivity of cancer
cells
Philchenkov et al., 2004 [101]
Caspase-based gene therapy Human caspase-3 gene therapy used in addition to etoposide treatment in an
AH130 liver tumour model reported to induce extensive apoptosis and reduce
tumour volume
Yamabe et al., 1999 [102]
Gene transfer of constitutively active caspse-3 into HuH7 human hepatoma cells
reported to selectively induce apoptosis
Cam et al., 2005 [103]
A recombinant adenovirus carrying immunocaspase 3 reported to exert anticancer
effect in hepatocellular carcinoma in vitro and in vivo
Li et al., 2007 [104]
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independent of TP53 status [88] while Yamaguchi et al
reported that targeting XIAP or Survivin by siRNAs sen-
sitise hepatoma cells to death receptor- and chemother-
apeutic agent-induced cell death [89].
4.3.2 Targeting Survivin
Many studies have investigated various approaches tar-
geting Survivin for cancer intervention. One example is
the use of antisense oligonucleotides. Grossman et al
was among the first to demonstrate the use of the anti-
sense approach in human melanoma cells. It was shown
that transfection of anti-sense Survivin into YUSAC-2
and LOX malignant melanoma cells resulted in sponta-
neous apoptosis in these cells [90]. The anti-sense
approach has also been applied in head and neck squa-
mous cell carcinoma and reported to induce apoptosis
and sensitise these cells to chemotherapy [91] and in
medullary thyroid carcinoma cells, and was found to
inhibit growth and proliferation of these cells [92].
Another approach in targeting Survivin is the use of siR-
NAs, which have been shown to downregulate Survivin
and diminish radioresistance in pancreatic cancer cells
[93], to inhibit proliferation and induce apoptosis in
SPCA1 and SH77 human lung adenocarcinoma cells
[94], to suppress Survivin expression, inhibit cell prolif-
eration and enhance apoptosis in SKOV3/DDP ovarian
cancer cells [95] as well as to enhance the radiosensitiv-
ity of human non-small cell lung cancer cells [96].
Besides, small molecules antagonists of Survivin such as
cyclin-dependent kinase inhibitors and Hsp90 inhibitors
and gene therapy have also been attempted in targeting
Survivin in cancer therapy (reviewed by Pennati et al.,
2007 [97]).
4.3.3 Other IAP antagonists
Other IAP antagonists include peptidic and non-peptidic
small molecules, which act as IAP inhibitors. Two cyclo-
peptidic Smac mimetics, 2 and 3, which were found to
bind to XIAP and cIAP-1/2 and restore the activities of
caspases- 9 and 3/-7 inhibited by XIAP were amongst
the many examples [98]. On the other hand, SM-164, a
non-peptidic IAP inhibitor was reported to strongly
enhance TRAIL activity by concurrently targeting XIAP
and cIAP1 [99].
4.4 Targeting caspases
4.4.1 Caspase-based drug therapy
Several drugs have been designed to synthetically acti-
vate caspases. For example, Apoptin is a caspase-indu-
cing agent which was initially derived from chicken
anaemia virus and had the ability to selectively induce
apoptosis in malignant but not normal cells [100].
Another class of drugs which are activators of caspases
are the small molecules caspase activators. These are
peptides which contain the arginin-glycine-aspartate
motif. They are pro-apoptotic and have the ability to
induce auto-activation of procaspase 3 directly. They
have also been shown to lower the activation threshold
of caspase or activate caspase, contributing to an
increase in drug sensitivity of cancer cells [101].
4.4.2 Caspase-based gene therapy
In addition to caspase-based drug therapy, caspase-based
gene therapy has been attempted in several studies. For
instance, human caspase-3 gene therapy was used in
addition to etoposide treatment in an AH130 liver
tumour model and was found to induce extensive apop-
tosis and reduce tumour volume [102] while gene trans-
fer of constitutively active caspse-3 into HuH7 human
hepatoma cells selectively induced apoptosis in these
cells [103]. Also, a recombinant adenovirus carrying
immunocaspase 3 has been shown to exert anti-cancer
effects in hepatocellular carcinoma in vitro and in vivo
[104].
4.5 Molecules targeting apoptosis in clinical trials
Recently, many new molecules that target apoptosis
enter various stages of clinical trials. A search at http://
www.clinicaltrials.gov (a registry and results database of
federally and privately supported clinical trials con-
ducted in the United States and around the world)
returns many results. These molecules target various
proteins involved in apoptosis. Many are antagonists of
IAPs and molecules that target the Bcl-2 family of pro-
teins. Table 3 summarises ongoing or recently com-
pleted clinical trials involving molecules that target
apoptosis.
5. Conclusions
The abundance of literature suggests that defects along
apoptotic pathways play a crucial role in carcinogenesis
and that many new treatment strategies targeting apop-
tosis are feasible and may be used in the treatment of
various types of cancer. Some of these discoveries are
preclinical while others have already entered clinical
trials. Many of these new agents or treatment strategies
have also been incorporated into combination therapy
involving conventional anticancer drugs in several clini-
cal trials, which may help enhance currently available
treatment modalities. However, some puzzling and trou-
bling questions such as whether these treatment strate-
gies induce resistance in tumours and whether they will
cause normal cells to die in massive numbers still
remain unanswered. This is a true concern if lessons
were to be learnt from the conventional anticancer
drugs, which wipe out both normal cells and tumour
cells and cause brutal side effects and tumour resistance.
On the other hand, it would be of clinical benefit, if
these molecules that target apoptosis are specifically act-
ing on a single pathway or protein. However, most of
the molecules that enter clinical trials act on several
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targets and these include many inhibitors of the Bcl-
family of proteins and some pan-IAP inhibitors. Hence,
evidence-based long-term follow ups on patients receiv-
ing these new cancer treatments are needed and
ongoing research should focus on those strategies that
can selectively induce apoptosis in malignant cells and
not the normal ones.
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